

Clinical Policy: Fertility Preservation

Reference Number: CP.MP.130

Date of Last Revision: 01/24

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Fertility may be transiently or permanently affected by medical treatments such as bilateral oophorectomy, gonadotoxic therapy, cytotoxic chemotherapy, or radiation therapy, as well as by other iatrogenic causes. Rates of permanent infertility and compromised fertility after medical treatment vary and depend on many factors, including the drug, size, and location of the radiation field if applicable, dose, dose-intensity, method of administration (oral versus intravenous), disease, age, treatment type and dosages, and pretreatment fertility.

Note: For criteria related to cryopreservation, please see CP.MP.55 Assisted Reproductive Technologies.

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® that, when a covered benefit under the member's/enrollee's benefit plan contract, any of the following procedures are **medically necessary** for adults and adolescents with a female reproductive system prior to commencing medically necessary treatment that is likely to cause infertility (excluding voluntary sterilization):
 - A. Ovarian stimulation and retrieval of oocytes;
 - B. Ovarian tissue retrieval and all of the following:
 1. Ovarian tissue is free from malignancy;
 2. Insufficient time for oocyte retrieval or member/enrollee is prepubertal;
 - C. Ovarian transposition (oophoropexy).

Note: For those with female reproductive systems \geq age 40 requesting retrieval of their own oocytes, documentation is required noting that the treating provider has evaluated age, infertility risk factors, measure of ovarian reserve, and considers use of the member/enrollee's own oocytes a viable strategy for attempting future conception.

- II. It is the policy of health plans affiliated with Centene Corporation that there is insufficient evidence in the published peer-reviewed literature to support the use of the following procedures for fertility preservation in adults and adolescents with a female reproductive system prior to commencing treatment that is likely to affect fertility:
 - A. Ovarian suppression with gonadotropin releasing hormone (GnRH) agonist or antagonists.
- III. It is the policy of health plans affiliated with Centene Corporation that, when a covered benefit under the member's/enrollee's benefit plan contract, the following procedures are **medically necessary** for adults and adolescents with a male reproductive system prior to commencing medically necessary treatment that is likely to cause infertility (excluding voluntary sterilization):

A. Sperm extraction and retrieval procedures.

IV. It is the policy of health plans affiliated with Centene Corporation that there is insufficient evidence in the published peer-reviewed literature to support the use of the following procedures for fertility preservation in adults and adolescents with a male reproductive system prior to commencing treatment that is likely to affect fertility:

- A. Testicular suppression with GnRH agonist or antagonists;
- B. Reimplantation or grafting of human testicular tissue.

Background

An estimated 4.4% of all new cancer cases occur among adolescents and young adults between the ages of 15 to 39. Cancer patients are surviving at increasing rates, but successful treatment in younger patients can often be gonadotoxic and lead to late and long-term effects such as infertility. Treatment can affect fertility by causing damage to immature eggs and reproductive organs and affecting the body's hormones. Fertility preservation is an essential part of the management of adolescents and young adults who are at risk for infertility due to cancer treatments.¹¹

Gonadotoxic treatments include chemotherapy, radiation, and surgical resection (for treatment of disease or gender affirmation surgery). Additionally, chemotherapy can be used for noncancerous conditions such as autoimmune diseases, like systemic lupus erythematosus (SLE), and hematological disease. Prompt counseling regarding available options for fertility preservation for iatrogenic infertility should be provided to patients prior to undergoing any gonadotoxic treatments.¹⁰

American Society for Reproductive Medicine (ASRM)^{10}*

The 2019 ASRM committee opinion for Fertility Preservation in Patients Undergoing Gonadotoxic Therapy or Gonadectomy affirmed that ovarian tissue cryopreservation is no longer considered experimental for prepubertal girls and for those who cannot delay cancer treatment to undergo ovarian stimulation and oocyte retrieval. The committee states, “data on the efficacy, safety, and reproductive outcomes after ovarian tissue cryopreservation are still limited. Given the current body of literature, ovarian tissue cryopreservation should be considered an established medical procedure with limited effectiveness that should be offered to carefully selected patients.”

The guideline states that the use of gonadotropin releasing hormone (GnRH) analogs for ovarian protection during chemotherapy remains controversial: “further studies are required to establish the efficacy of this treatment and to determine which patients are the best candidates for its use.” Furthermore, GnRH analog therapy for fertility preservation in males has failed to demonstrate effectiveness.

American Society of Clinical Oncology (ASCO)^{5}*

The ASCO recommends discussing fertility preservation with all patients of reproductive age (and with parents or guardians of children and adolescents) if infertility is a potential risk of therapy, as early as possible, before treatment starts.

For those with a male reproductive system who express an interest in fertility preservation, sperm cryopreservation is the only established fertility preservation method. ASCO notes that in these patients, hormonal therapy has not shown to be successful in preserving fertility. Per ASCO, other methods, including testicular tissue cryopreservation for the purpose of future reimplantation or grafting of human testicular tissue, are experimental.

For those with a female reproductive system who express an interest in fertility preservation, both embryo and oocyte cryopreservation are established fertility preservation methods. The ASCO notes that evidence for ovarian tissue cryopreservation for the purpose of future transplantation remains insufficient, however, the field of ovarian tissue cryopreservation is advancing quickly and may evolve to become standard therapy in the future though it should also be noted that further investigation is needed to confirm whether it is safe in patients with leukemias. They note also, there is insufficient evidence regarding the effectiveness of ovarian suppression with GnRH agonist or antagonists to preserve fertility.

National Comprehensive Cancer Network (NCCN)^{8}*

NCCN guidelines on Adolescent and Young Adult Oncology note that oocyte or embryo cryopreservation is recommended for those that can delay cancer therapy for approximately three weeks. Ovarian tissue cryopreservation is a promising strategy for fertility preservation when there is insufficient time for oocyte or embryo cryopreservation and/or the patient is prepubertal. Hormonal stimulation is not required with this technique, therefore there is no delay in the initiation of treatment. This procedure is not appropriate for certain patients, including carriers of BRCA mutations due to the increased risk of ovarian cancer and those with cancer if potential exists for reintroduction of malignant cells with grafting. While ovarian tissue cryopreservation is still considered investigational at some institutions, it may be discussed as an option for fertility preservation.

Some data suggests menstrual suppression with GnRH agonists may protect ovarian function. However, evidence that menstrual suppression with GnRH agonists provides adequate protection of the ovaries is controversial, so this procedure is not currently considered a form of fertility preservation.

American College of Obstetricians and Gynecologists (ACOG)^{6}*

ACOG's Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors committee opinion states that "cryopreservation of oocytes or embryos may be offered before cancer treatments if there is adequate time and a safe method for ovarian stimulation. Ovarian tissue extraction and cryopreservation have been shown to have some success with posttreatment autotransplantation after chemotherapy."

For young individuals with a female reproductive system who have completed sexual development, GnRH agonists and antagonists such as leuprolide acetate, have been used to induce ovarian quiescence to preserve ovarian function and fertility after cytotoxic treatment. Leuprolide acetate is not recommended prior to puberty. There still is no conclusive evidence that demonstrates efficacy of GnRH agonists and antagonists, and studies are primarily observational regarding their effectiveness in fertility preservation.

**Note: For criteria related to cryopreservation, please see CP.MP.55 Assisted Reproductive Technologies.*

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2022, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
00840	Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified
00922	Anesthesia for procedures on male genitalia (including open urethral procedures); seminal vesicles
53899	Unlisted procedure, urinary system
55870	Electroejaculation
55899	Unlisted procedure, male genital system
58825	Transposition, ovary(s)
58970	Follicle Puncture for oocyte retrieval, any method
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete
76948	Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation
82670	Estradiol; total
83001	Gonadotropin; follicle stimulating hormone (FSH)
83002	Gonadotropin; luteinizing hormone (LH)
84144	Progesterone
84702	Gonadotropin; chorionic (hCG); quantitative
89254	Oocyte identification from follicular fluid
89320	Semen analysis; volume, count motility and differential
99000	Handling and/or conveyance of specimen for transfer from office to a laboratory
99001	Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)
99070	Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided)
99078	Physician or other qualified health care professional qualified by education, training, licensure/regulation (when applicable) educational services in a group setting (eg, prenatal, obesity, or diabetic instructions)
99199	Unlisted special service, procedure or report

HCPCS Codes	Description
S4028	Microsurgical epididymal sperm aspiration (MESA)

CPT Codes that do not support medical necessity

CPT® Codes	Description
53899	Unlisted procedure, urinary system
55899	Unlisted procedure, male genital system
89398	Unlisted reproductive medicine laboratory procedure

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy adopted from Health Net NMP512, Fertility Preservation in Cancer Patients. Expanded criteria to include iatrogenic causes of infertility. Added the following ICD-10 codes: D27.0, D27.1, N70.03, N70.13, N83.51.	9/16	10/16
Annual review completed. Codes reviewed. References reviewed and updated. Specialty review completed.	09/19	09/19
Removed CPT 0375T – code deleted 1/1/20	04/20	
References reviewed and updated. Replaced ‘members’ with ‘members/enrollees’ in all instances. Specialty review completed.	09/20	09/20
Revised description of CPT-82670. CPT-0058T deleted in 2021. ‘‘Experimental/investigational’’ verbiage replaced with descriptive language in policy statement III and IV.	02/21	
Annual review. References reviewed and updated. Changed ‘‘review date’’ in the header to ‘‘date of last revision’’ and ‘‘date’’ in the revision log header to ‘‘revision date.’’	09/21	09/21
Annual review. Replaced all instances of female and male with descriptive, gender-neutral verbiage. Added code 89398 to table of CPT codes considered investigational. References reviewed and updated.	05/22	05/22
In description, removed ‘‘male and female’’ from introductory sentence about medical causes of impaired fertility.	09/22	
Annual review. Specified in sections I. and III. that the treatment causing risk to fertility was medically necessary. Removed ‘‘embryo cryopreservation’’, ‘‘cryopreservation of mature oocytes’’, ‘‘conservative gynecologic surgery (radical trachelectomy and ovarian cystectomy)’’ and ‘‘radiation (gonadal) shielding’’ from section I. Added ‘‘ovarian stimulation and retrieval of oocytes’’ and ‘‘ovarian tissue retrieval’’ to section I. Included ‘‘Note: For those with female reproductive systems > age 40...’’ to criteria and background sections. Removed ‘‘cryopreservation of immature oocytes’’ and ovarian tissue cryopreservation and transplantation procedures’’ from section II. Added ‘‘sperm extraction procedures and retrieval procedures’’ to section III and removed ‘‘cryopreservation of sperm’’ and radiation (gonadal) shielding’’. Removed ‘‘testicular tissue or spermatogonial cryopreservation’’ from	05/23	05/23

Reviews, Revisions, and Approvals	Revision Date	Approval Date
section IV. Criteria section reformatted for organizational purposes. Background updated. Added CPT codes 00922, 53899, 55899, and 55870. Removed CPT codes 57531, 77334, 89250, 89251, 89258, 89259, 89268, 89272, 89280, 89281, 89337, 89352, 89353. Added HCPCS codes S4028 and removed HCPCS codes S4030 and S4031. Added CPT code 53899 and 55899 and removed 89335 from the "does not support" table. References reviewed and updated. Internal specialist review.		
Annual review. Minor rewording under description and background with no impact to criteria. References reviewed and updated. Reviewed by internal specialist.	01/24	01/24

References

1. Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. *Fertil Steril*. 2014;101(5):1237 to1243. doi:10.1016/j.fertnstert.2014.02.052
2. Shah JS, Guerra R, Bodurka DC, Sun CC, Chisholm GB, Woodard TL. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. *Gynecol Oncol*. 2017;147(3):497 to502. doi:10.1016/j.ygyno.2017.09.019
3. Health Technology Assessment. Ovarian tissue cryopreservation for preservation of fertility in patients undergoing gonadotoxic cancer treatment. Hayes. www.hayesinc.com. Published October 1, 2019 (annual review December 8, 2022). Accessed November 9, 2023.
4. Pacheco F, Oktay K. Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. *Reprod Sci*. 2017;24(8):1111 to1120. doi:10.1177/1933719117702251
5. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients with Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36(19):1994 to2001. doi:10.1200/JCO.2018.78.1914
6. The American College of Obstetricians and Gynecologists. Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors No.747. www.acog.org. Published July 2018 (reaffirmed 2021). Accessed November 9, 2023.
7. Sonmezer M, Oktay K. Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery. UpToDate. www.uptodate.com. Published July 8, 2022. . Accessed November 9, 2023.
8. National Comprehensive Cancer Network. Adolescent and Young Adult (AYA) Oncology (Version 3.2023). https://www.nccn.org/guidelines/category_4. Accessed November 9, 2023.
9. Oktay K, Sonmezer M. Fertility preservation: Cryopreservation options. UpToDate. www.uptodate.com. Published February 13, 2023. Accessed November 9, 2023.
10. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. *Fertil Steril*. 2019;112(6):1022 to 1033. doi:10.1016/j.fertnstert.2019.09.013
11. National Cancer Institute. Adolescents and Young Adults with Cancer. <https://www.cancer.gov/types/aya>. Published April 24, 2023. Accessed November 9, 2023.

12. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. *Cancer*. 2009;115(18):4118-4126.
doi:<https://doi.org/10.1002/cncr.24461>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited.

Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.